ProCE Banner Series

Managing Patients With High-Risk Hepatocellular Carcinoma: Critical Considerations for the Interdisciplinary Team

Join us for a live, 1-hour CME/CNE/CPE-certified workshop series and engage with an expert who will discuss current and emerging strategies in the management of high-risk hepatocellular carcinoma (HCC).

To Register:  Please click the green “Learn More” button below. On the next page, select “Register for Virtual Event”. Once registered, you will receive a confirmation email. Follow-up emails with details will be sent as the event nears.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This educational program is intended for oncology physicians, surgeons, hepatologists, interventional radiologists and other healthcare professionals who care for patients with hepatocellular carcinoma.

All Events

Past Events

February

06

2024

Managing Patients With High-Risk Hepatocellular Carcinoma: Critical Considerations for the Interdisciplinary Team

3:30 PM - 4:30 PM Mountain Time (MT)

Virtual

Virtual Event | Host Group in NM, Rio Rancho, New Mexico

April

09

2024

Managing Patients With High-Risk Hepatocellular Carcinoma: Critical Considerations for the Interdisciplinary Team [Open Registration]

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group MI, Royal Oak, Michigan

May

16

2024

Managing Patients With High-Risk Hepatocellular Carcinoma: Critical Considerations for the Interdisciplinary Team [Open Registration]

11:30 AM - 12:30 PM Eastern Time (ET)

Virtual

CCO Simulcast | Host Group DC, Washington, District of Columbia

Faculty

ProCE Banner Faculty
Richard Finn, MD

Associate Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

ProCE Banner Faculty
Thomas B. Karasic, MD

Physician Leader, Developmental Therapeutics
Assistant Professor of Medicine
Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

ProCE Banner Faculty
Michael Morse, MD

Professor of Medicine
GI Oncology
Duke University Health System
Durham, North Carolina

ProCE Banner Faculty
Neehar Parikh, MD, MS

Associate Professor
Medical Director, Liver Tumor Program
Division of Gastroenterology & Hepatology
University of Michigan
Ann Arbor, Michigan

ProCE Banner Faculty
Anjana Pillai, MD, FAST, FAASLD

Associate Professor of Medicine
Division of Gastroenterology, Hepatology and Nutrition
Center for Liver Diseases
University of Chicago Medicine
Chicago, Illinois

ProCE Banner Faculty
Amit Singal, MD, MS

Professor of Medicine
Medical Director of Liver Tumor Program
Chief of Hepatology
UT Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

ProCE Banner Faculty
Tamar H. Taddei, MD

Professor of Medicine, Digestive Diseases
Vice Chief of Faculty Development, Digestive Diseases
Yale School of Medicine
Chief of Gastroenterology
VA Connecticut Health Care System
West Haven, Connecticut

ProCE Banner Faculty
Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Topics

Welcome and Introduction

Overview of HCC Pathogenesis, Staging, and Definition of High Risk

Treatment of High-Risk Early-Stage HCC

Emerging Adjuvant Therapies for High-Risk HCC

Final Thoughts and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with high-risk HCC. 

Target Audience
This educational program is intended for oncology physicians, surgeons, hepatologists, interventional radiologists and other healthcare professionals who care for patients with hepatocellular carcinoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain to colleagues and patients key factors that determine a patient with HCC to be at high risk of recurrence, including pathogenesis and staging
  • Plan a personalized therapeutic strategy for patients with early-stage HCC at high risk of recurrence considering all available treatment modalities and expert recommendations regarding timing and sequencing of therapy
  • Assess the rationale and available clinical trial data evaluating the use of immune checkpoint inhibitors for patients with high-risk HCC in the adjuvant setting

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-24-027-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Genentech, a member of the Roche Group.